Previous 10 | Next 10 |
home / stock / flhlf / flhlf news
FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES Canada NewsWire Filament subsidiary Psilo Scientific manufactured the drug product on behalf of PharmAla for distribution to clinical trial customers and authorized patients. VANCOUVER, BC ...
FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , March 31, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage ...
FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING PSILOCYBIN FOR METHAMPHETAMINE USE DISORDER Canada NewsWire The clinical trial will study PEX010, Filament's botanical psilocybin drug candidate VANCOUVER, BC , March 15, 2023 /CNW...
FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Canada NewsWire CAMH will study PEX010, Filament's botanical psilocybin drug candidate, in a Health Canada-approved clinical trial for mild cognitive impairment ...
Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults SAN FRANCISCO, CA / ACCESSWIRE / January 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) t...
FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN Canada NewsWire Danish psychiatric research hospital will study the effects of Filament's natural psilocybin drug candidate for treating alcohol use disorder VANCOUVER...
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses Canada NewsWire New venture aligns with Jaguar's mental health Entheogen Therapeuti...
FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD OF DIRECTORS Canada NewsWire VANCOUVER, BC , Dec. 30, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychede...
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on...
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc ( CSE:PSYG |...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion o...
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...